Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Consensus: Moderate Buy — Fourteen analysts cover Amylyx, with a breakdown of 1 sell, 2 holds, 9 buys and 2 strong buys, and an average 12‑month target price of $20.11; several firms raised targets recently (Guggenheim to $30, HC Wainwright $34, BofA to $19).
• Stock snapshot: shares opened at $17.32, trade near a 52‑week high of $17.49 (52‑week low $3.30), market cap ~$1.91 billion, and the company slightly beat quarterly EPS estimates ($‑0.30 vs. $‑0.31).
• Ownership and insider activity: insiders sold about 140,162 shares (~$1.9M) over the past three months (including CEO sales) while insiders still own 12.30% of the stock and institutional/hedge funds control roughly 95.84%.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the fourteen research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, nine have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $20.1111.

A number of brokerages recently issued reports on AMLX. Wall Street Zen upgraded Amylyx Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, March 7th. Guggenheim increased their price target on shares of Amylyx Pharmaceuticals from $25.00 to $30.00 and gave the stock a "buy" rating in a report on Thursday, March 19th. Weiss Ratings reissued a "sell (d-)" rating on shares of Amylyx Pharmaceuticals in a report on Monday, December 29th. HC Wainwright reissued a "buy" rating and issued a $34.00 price target on shares of Amylyx Pharmaceuticals in a report on Wednesday, March 25th. Finally, Bank of America increased their price target on shares of Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the stock a "buy" rating in a report on Friday, February 20th.

Amylyx Pharmaceuticals Stock Performance

Shares of Amylyx Pharmaceuticals stock opened at $17.32 on Friday. Amylyx Pharmaceuticals has a 52-week low of $3.30 and a 52-week high of $17.49. The stock's 50-day simple moving average is $14.41 and its 200 day simple moving average is $13.91. The stock has a market capitalization of $1.91 billion, a P/E ratio of -11.17 and a beta of -0.22.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.01. Equities research analysts forecast that Amylyx Pharmaceuticals will post -2.2 EPS for the current fiscal year.

Insider Transactions at Amylyx Pharmaceuticals

In other news, CEO Joshua B. Cohen sold 1,974 shares of the stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $13.83, for a total value of $27,300.42. Following the sale, the chief executive officer directly owned 3,379,465 shares of the company's stock, valued at approximately $46,738,000.95. This represents a 0.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Justin B. Klee sold 1,995 shares of the stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $13.89, for a total transaction of $27,710.55. Following the completion of the sale, the chief executive officer directly owned 3,379,398 shares in the company, valued at approximately $46,939,838.22. The trade was a 0.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 140,162 shares of company stock worth $1,905,874. Insiders own 12.30% of the company's stock.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Landscape Capital Management L.L.C. lifted its holdings in shares of Amylyx Pharmaceuticals by 17.5% in the fourth quarter. Landscape Capital Management L.L.C. now owns 12,226 shares of the company's stock worth $148,000 after buying an additional 1,825 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Amylyx Pharmaceuticals by 54.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,337 shares of the company's stock worth $64,000 after purchasing an additional 1,890 shares during the last quarter. Meeder Asset Management Inc. bought a new position in shares of Amylyx Pharmaceuticals in the fourth quarter worth approximately $25,000. China Universal Asset Management Co. Ltd. increased its position in shares of Amylyx Pharmaceuticals by 14.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 17,895 shares of the company's stock worth $216,000 after purchasing an additional 2,265 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in shares of Amylyx Pharmaceuticals by 13.4% in the fourth quarter. The Manufacturers Life Insurance Company now owns 26,988 shares of the company's stock worth $326,000 after purchasing an additional 3,198 shares during the last quarter. 95.84% of the stock is owned by hedge funds and other institutional investors.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company's lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.